The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

New Study Shows Promising Results for COPD Treatment Nov. 20, 2024 — A new study shows that a form of vitamin B3 can reduce lung inflammation in COPD patients. The researchers hope it will pave ...

There is an increasing interest in the frequency of COPD exacerbations, since this was found to relate to prevention and treatment. Most of the new drugs being investigated and developed are ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

A new method of scanning lungs is able to show in real time how air moves in and out of the lungs as people take a breath in patients with asthma, chronic obstructive pulmonary disease (COPD), and ...

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globallyCombined in-licensing and financing for a novel long-acting clinical ...

Demonstrating that the scans work in patients with asthma or COPD, the team comprising experts from across ... This shows ...

The outlook for end-stage COPD varies from person to person. Your outlook may depend on a number of factors, such as: Treatments for COPD can’t reverse damage that’s already been done ...